10 Best US Stocks to Buy Under $25

Page 1 of 3

US stocks have delivered significant returns in 2026 amid heightened market volatility and shifting investor sentiment. While the Nasdaq 100 is down by 11% from its all-time highs, it is still up by 12% for the year, affirming the strong upward momentum.

The technology sector has been a key driver of market performance and sentiment, benefiting from a sustained artificial intelligence boom. Meanwhile, strong corporate earnings have also helped catapult some stocks to record highs and support broader market valuations.

However, concerns over inflation, interest rates, geopolitical tensions, and elevated valuations have contributed to periods of heightened volatility, triggering significant corrections. Heading into year-end, opportunities are increasingly cropping up amid rotation out of large artificial intelligence stocks.

Wall Street bull Dan Ives insists the recent correction fueled by AI sell off presents a golden buy opportunity just like during Covid. Explore some of the best us stocks to invest in for long term amid the recent sell off.

Stocks trading below $25 provide investors an opportunity to gain exposure to promising US companies. While a low share price does not necessarily mean a stock is undervalued, several companies trading at these levels offer compelling investment opportunities. Their long-term prospects also remain positive, supported by improving financial performance, growing businesses, attractive valuations, and long-term growth prospects.

10 Best US Stocks to Buy Under $25

From technology and healthcare to financial services and energy, some of these companies are benefiting from powerful industry trends that could support future earnings growth. Some of the small-cap value stocks to invest in now are trading at a discount following recent market sell-offs, potentially creating attractive entry points.

In this article, we detail some of the best US stocks to buy under $25, focusing on companies with solid fundamentals, attractive growth opportunities, and the potential to deliver meaningful long-term value.

Our Methodology

To compile our list of the 10 Best US Stocks to Buy Under $25, we looked for US companies whose revenue growth has exceeded 20% over the past 5 years. Next, we focused on the top 10 stocks most favored by institutional investors as we detailed hedge funds holding stakes in them. Finally, the 10 best US stocks to invest in for the long term were ranked in ascending order by the number of hedge funds holding stakes at the end of the second quarter.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

10. First Advantage Corporation (NASDAQ:FA)

Share Price as of November 17: $21.43

Year-to-Date Gain: 49.89%

5-Year Revenue Growth: 25.33%

Number of Hedge Fund Holders: 16

First Advantage Corporation (NASDAQ:FA) is one of the best US stocks to buy under $25 as it increasingly benefits from improving demand for background screening, identity verification, and workforce-related services. The stock is up more than 40% as investors react to accelerating revenue growth, stronger earnings, and improving hiring activity.

The company’s third-quarter results were particularly encouraging, with revenue up 13.8% to $465.8 million and adjusted earnings per share up 26.7% to $0.38. The earnings improvement suggests that the company is converting its growing revenue base into stronger profitability.

Management also raised full-year revenue guidance to between $1.720 billion and $1.745 billion and expects adjusted diluted earnings per share of $1.30 to $1.33. The revised outlook signals management’s confidence that business momentum will continue through the remainder of the year. Is AI disruption a significant risk for First Advantage?

First Advantage Corporation’s integration of Sterling Check has also strengthened its long-term growth prospects. The acquisition expands its customer base, geographic reach, technology capabilities, and screening services. The company is also increasingly investing in proprietary data, automation, and artificial intelligence.

Wall Street is already taking note of First Advantage Corporation firing on all angles. On November 10, Citigroup raised the stock price target to $25 from $22 while reiterating a Neutral rating.

9. ImmunityBio, Inc. (NASDAQ:IBRX)

Share Price as of November 17: $5.98

Year-to-Date Gain: 196.04%

5-Year Revenue Growth: 299.74%

Number of Hedge Fund Holders: 27

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best US stocks to buy under $25 for investors seeking exposure to the rapidly growing biotechnology and cancer-immunotherapy industry. The stock has rallied about 200% as investors react to optimism about the company’s cancer immunotherapy drug ANKTIVA.

ANKTIVA net product revenue rose 53% in the third quarter to $48.7 million, driven by continued adoption in the US and strong market uptake. Net product revenue was up 92% for the first nine months of the year to $143.6 million, affirming the company’s transition from clinical development to commercial revenue generation.

ImmunityBio, Inc. has already received a significant boost from the FDA, expanding ANKTIVA’s approval to cover additional patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). The approval expands the company’s target base and is expected to strengthen commercial opportunities. In addition, the company is pursuing growth opportunities in Europe and other international markets to expand its commercial reach. What’s up with $5.8B cancer market opportunity for ImmunityBio?

The company is also staring at additional clinical and regulatory catalysts after Cohort A in its randomized QUILT-2.005 trial met its primary endpoint. Further regulatory approvals could expand the drug’s commercial potential and provide additional catalysts for the stock.

ImmunityBio, Inc. had approximately $334.3 million in cash and cash equivalents and marketable securities as of September, expected to support commercialization, clinical development, and international expansion.

Amid the solid underlying fundamentals, Jefferies raised its price target to $14 from $12 and reiterated a Buy rating on October 14. Piper Sandler also hiked its price target to $16 from $12 following the significant regulatory milestones.

Page 1 of 3